Norwest Venture Partners nearing 40 percent acquisition in Regency Healthcare for Rs 600 crore

Published On 2023-09-28 07:30 GMT   |   Update On 2023-09-28 14:59 GMT

New Delhi: Norwest Venture Partners is reportedly on the verge of acquiring a 40% stake in Regency Healthcare in a deal amounting up to ₹600 crore. The transaction will encompass both an expansion of the equity base and a transfer of existing shares to the buyer, backed by Wells Fargo, sources familiar with the matter informed ET.

Wells Fargo, the US banking giant, is the principal institutional limited partner in Norwest Venture Partners. It's anticipated that Norwest and Regency Healthcare will finalize an agreement within the forthcoming two weeks, the aforementioned sources disclosed.

Advertisement

Regency Healthcare, promoted by Kanpur-based Atul Kapoor, operates a sizable 1,000-bed hospital in the city. Additionally, in a joint venture with Germany's Fresenius Medical Care, a global frontrunner in managing end-stage kidney diseases, it administers dialysis clinics. Back in 2016, International Finance Corporation (IFC) and HealthQuad invested roughly $14 million in Regency HealthcareBoth will exit as part of the arrangement.

IFC, functioning as the private investment arm of the World Bank, had previously detailed its investment rationale in a public note. It highlighted that the funds would bolster the expansion of hospital beds in Uttar Pradesh, a region notably lacking in healthcare infrastructure. Notably, Regency was in the process of establishing the first cancer hospital in Uttar Pradesh when the investment was initiated. HealthQuad, a healthcare-centric venture capital fund, had mobilized a second fund of $162 million last March with backing from several global investors, led by biopharmaceutical giant MSD - Merck, Sharp & Dohme.

Norwest Venture Partner manages a robust $12.5-billion investment portfolio across North America, Israel, and India. Some of its active investments include stakes in Xpressbees logistics, Duroflex, and Swiggy. It had also previously invested in Thyrocare and RBL Bank.

Read also: Sanofi Dupixent sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for USFDA priority review


Tags:    
Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News